VYNE THERAPEUTICS INC (VYNE) Stock Price, Forecast & Analysis
USA - NASDAQ:VYNE - US92941V3087 - Common Stock
VYNE Key Statistics, Chart & Performance
The current stock price of VYNE is 0.3533 USD. In the past month the price decreased by -4.78%. In the past year, price decreased by -88.85%.
VYNE Latest News, Press Relases and Analysis
VYNE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.2 | 919.89B | ||
| JNJ | JOHNSON & JOHNSON | 17.96 | 449.03B | ||
| MRK | MERCK & CO. INC. | 9.76 | 214.76B | ||
| PFE | PFIZER INC | 7.6 | 138.27B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.14 | 95.33B | ||
| ZTS | ZOETIS INC | 18.92 | 53.16B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.47 | 22.71B | ||
| VTRS | VIATRIS INC | 4.31 | 11.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.11 | 11.02B | ||
| CORT | CORCEPT THERAPEUTICS INC | 82.88 | 7.68B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.93B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.3 | 4.04B |
Related stock screener links
About VYNE
Company Profile
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 13 full-time employees. The company went IPO on 2018-01-25. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Company Info
VYNE THERAPEUTICS INC
685 Route 202/206 N., Suite 301
Bridgewater NEW JERSEY 08807 US
CEO: David Domzalski
Employees: 13
Phone: 18007757936
VYNE THERAPEUTICS INC / VYNE FAQ
What does VYNE do?
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 13 full-time employees. The company went IPO on 2018-01-25. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
What is the current price of VYNE stock?
The current stock price of VYNE is 0.3533 USD. The price increased by 0.28% in the last trading session.
What is the dividend status of VYNE THERAPEUTICS INC?
VYNE does not pay a dividend.
How is the ChartMill rating for VYNE THERAPEUTICS INC?
VYNE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is VYNE THERAPEUTICS INC (VYNE) stock traded?
VYNE stock is listed on the Nasdaq exchange.
Would investing in VYNE THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VYNE.
VYNE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VYNE. When comparing the yearly performance of all stocks, VYNE is a bad performer in the overall market: 95.36% of all stocks are doing better.
VYNE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VYNE. VYNE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VYNE Financial Highlights
Over the last trailing twelve months VYNE reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS increased by 9.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.2% | ||
| ROE | -99.13% | ||
| Debt/Equity | 0 |
VYNE Forecast & Estimates
10 analysts have analysed VYNE and the average price target is 3.32 USD. This implies a price increase of 838.3% is expected in the next year compared to the current price of 0.3533.
For the next year, analysts expect an EPS growth of 24.77% and a revenue growth -62.5% for VYNE